Researchers have discovered a family of enzymes that work to reduce IgG-mediated pathologies in diseases like MG. The findings, involving mouse models, show that a specific enzyme (an endoglycosidase called CU43) was particularly effective in treating those diseases caused by overactive antibodies.
